NCT05858788View on ClinicalTrials.gov

A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

July 17, 2023

Study Completion Date

July 17, 2023

Conditions
Rheumatoid Arthritis
Interventions
DRUG

SAR441566

Tablet

Trial Locations (1)

91206

Parexel International-Site Number:8400001, Glendale

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT05858788 - A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants. | Biotech Hunter | Biotech Hunter